



Original Article

A high-fidelity RNA-targeting Cas13 restores paternal *Ube3a* expression and improves motor functions in Angelman syndrome mice

Jinhui Li ^{1 6}, Zhixin Shen ^{1 6}, Yajing Liu ^{1 6}, Zixiang Yan ^{3 6}, Yuanhua Liu ^{1 6}, Xiang Lin ⁴, Junjie Tang ¹, Ruimin Lv ¹, Guannan Geng ¹, Zhi-Qi Xiong ¹, Changyang Zhou ¹, Hui Yang ^{1 2 5}

Show more

Add to Mendeley Share Cite

https://doi.org/10.1016/j.ymthe.2023.02.015 Get rights and content

Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by <u>loss of function mutations</u> in maternally expressed <u>UBE3A</u>. No gene-specific treatment is available for patients so far. Although intact and transcriptionally active, paternally inherited <u>UBE3A</u> is silenced by elongation of antisense <u>long noncoding RNA UBE3A-ATS</u> in neurons. Here, we demonstrated that RNA targeting of paternal <u>Ube3a-ATS</u> with a high-fidelity CRISPR-Cas13 (hfCas13x.1) system could restore <u>Ube3a</u> expression to similar levels as that of maternal <u>Ube3a</u> in the cultured mouse neurons. Furthermore, injection into lateral ventricles with neuron-specific <u>hSyn1</u> promoter-driven hfCas13x.1 packaged in adeno-associated virus (AAV-PHP.eb) could restore paternal <u>Ube3a</u> expression in cortex and hippocampus of neonatal AS mice for up to 4 months after treatment. Behavioral tests showed that expression of paternal <u>Ube3a</u> significantly alleviated AS-related symptoms, including obesity and motor function. Our results suggested that hfCas13x.1-mediated suppression of the <u>Ube3a-ATS lncRNA</u> potentially serves as a promising targeted intervention for AS.

Graphical abstract

Jinhui Li 1 6, Zhixin Shen 1 6, Yajing Liu 1 6, Zixiang Yan 3 6, Yuanhua Liu 1 6, Xiang Lin 4, Junjie Tang 1, Ruimin Lv 1, Guannan Geng 1, Zhi-Qi Xiong 1, Changyang Zhou 1, Hui Yang 1 2 5

1

Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai 200031, China

2

Shanghai Center for Brain Science and Brain-Inspired Intelligence Technology, Shanghai 201210, China

3


Shenzhen Branch, Guangdong Laboratory for Lingnan Modern Agriculture, Genome Analysis Laboratory of the Ministry of Agriculture, Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen 518000, China

4

Department of Neurology and Institute of Neurology, The First Affiliated Hospital, Institute of Neuroscience, Fujian Medical University, #20, Chazhong Road, Taijiang District, Fuzhou 350005, China

5

HuidaGene Therapeutics Co., Ltd., Shanghai 200131, China Received 6 September 2022, Accepted 16 February 2023, Available online 18 February 2023.



Download: Download high-res image (103KB)

Download: Download full-size image

Key Words

Angelman syndromeRNA editinghigh-fidelity Cas13paternal Ube3amotor function

Data and code availability

All RNA-seq data have been deposited in the NCBI SRA under project accession number PRJNA842160. Source data are provided in this paper.

Cited by (o)

6

These authors contributed equally

View full text

© 2023 The American Society of Gene and Cell Therapy.